Press coverage about Repros Therapeutics (NASDAQ:RPRX) has trended positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Repros Therapeutics earned a daily sentiment score of 0.31 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44.2950142566003 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Separately, S&P Equity Research lowered their price target on Repros Therapeutics from $0.49 to $0.39 in a research report on Monday, November 20th.

Shares of Repros Therapeutics (NASDAQ RPRX) opened at $0.67 on Friday. Repros Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.33. The company has a market capitalization of $26.50, a PE ratio of -1.34 and a beta of 0.45.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Monday, November 13th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.24. Repros Therapeutics had a negative return on equity of 894.22% and a negative net margin of 4,242.73%. The company had revenue of $0.30 million during the quarter.

WARNING: “Positive Media Coverage Somewhat Unlikely to Impact Repros Therapeutics (RPRX) Stock Price” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Insider Buying and Selling by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with's FREE daily email newsletter.